Search results
Results from the WOW.Com Content Network
Ovarian hyperstimulation syndrome (OHSS) is a medical condition that can occur in some women who take fertility medication to stimulate egg growth, and in other women in sporadic cases. Most cases are mild, but rarely the condition is severe and can lead to serious illness or even death.
Any developing signs of OHSS will typically vanish at that point. However, in rare cases, severe OHSS can continue to develop. Reduced success rates have been reported in fresh embryo transfers when the agonist trigger is used without hCG, so that most centers will freeze all embryos in cycles triggered only with the agonist.
In rare cases, OHSS can kidney failure as well as blood clots; in very rare cases, OHSS can be life-threatening: In 2022, a 23-year-old woman from India died during an IVF procedure as OHSS caused ...
OHSS is characterized as cystic enlargement of the ovaries. Multiple birth is especially deleterious due to compounding risks including premature delivery and low birthweight, pre-eclampisa, and increased risk of neonatal mortality. While triplet births have been declining in ART, multiple births remain over 50% of births from IVF.
Usually, affected men show no symptoms, although they may have smaller testes. Men with this condition may exhibit azoospermia (no sperm production), oligozoospermia (small number of sperm production), or they may produce abnormally shaped sperm (teratozoospermia). [20] This case of infertility occurs during the development of gametes in the male.
That IVF doctor had never seen me in person, hadn’t examined me, or done more than glance at my records, but in her mind, my weight was the only thing holding me back from a successful pregnancy ...
A man who was “worried” about his fiancée coming home unusually late after work — notably, at 4 a.m. — is wondering if he’s “out of line” for asking her to let him know in the ...
A Cochrane review estimated that using GnRH agonist instead of hCG in IVF decreases the risk of mild, moderate or severe OHSS with an odds ratio of approximately 0.15. The review estimated that, for a woman with a 5% risk of mild, moderate or severe OHSS with the use of HCG, the risk of OHSS with the use of a GnRH agonist would be between 0 and ...